Literature DB >> 12746780

Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study.

F Bonnet1, M Bonarek, P Morlat, P Mercié, M Dupon, M C Gemain, D Malvy, N Bernard, J L Pellegrin, J Beylot.   

Abstract

A case-control study was undertaken to determine risk factors for lactic acidosis in human immunodeficiency virus-infected patients treated with nucleoside reverse-transcriptase inhibitors (NRTIs). From May 1996 to June 2000, 9 patients with lactic acidosis (defined as a plasma lactic acid level of >5 mM and plasma pH of <7.38) were identified. Control patients were randomly selected from among a large cohort of patients who initiated a dual NRTI regimen in 1996 or after. Two factors were associated with an increased risk of lactic acidosis: first, a creatinine clearance of <70 mL/min before lactic acidosis (OR, 15.8 [range, 3.0-86.5], P<10(-4)), and, second, a low nadir CD4+ T lymphocyte count before the inception of NRTI therapy (OR, 8.4 [range, 1.2-infinity], P=.03). The total cumulative exposure to NRTIs was not associated with an increased risk of lactic acidosis, nor was the cumulative exposure to any of the 4 NRTIs studied. According to these results, monitoring of creatinine clearance, especially in patients with a low nadir CD4+ T lymphocyte count, could lead to modifications in antiretroviral therapy in order to diminish the risk of occurrence of lactic acidosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746780     DOI: 10.1086/374601

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Second assessment of NeuroAIDS in Africa.

Authors:  Kevin Robertson; Kathy Kopnisky; James Hakim; Concepta Merry; Noeline Nakasujja; Colin Hall; Moussa Traore; Ned Sacktor; David Clifford; Charles Newton; Annelies Van Rie; Penny Holding; Janice Clements; Christine Zink; Jens Mielk; Mina Hosseinipour; Umesh Lalloo; Farida AMod; Christina Marra; Scott Evans; Jeff Liner
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

2.  Evaluation of effect of impaired renal function on lamivudine pharmacokinetics.

Authors:  Naïm Bouazza; Jean-Marc Tréluyer; Jade Ghosn; Déborah Hirt; Sihem Benaboud; Frantz Foissac; Jean-Paul Viard; Saik Urien
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 3.  Pharmacologically-induced metabolic acidosis: a review.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

4.  Hyperlactatemia and concurrent use of antiretroviral therapy among HIV infected patients in Uganda.

Authors:  M Waiswa; B B Byarugaba; P Ocama; H Mayanja-Kizza; E Seremba; S Ganguli; M Crowther; R Colebunders
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

5.  Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.

Authors:  Pierre Côté; Jean-Guy Baril; Marie-Nicole Hébert; Marina Klein; Richard Lalonde; Marc Poliquin; Danielle Rouleau; Rachel Therrien; Sylvie Vézina; Bernard Willems; Harold Dion; Patrice Junod; Normand Lapointe; Dominic Lévesque; Lyse Pinault; Cécile Tremblay; Benoît Trottier; Sylvie Trottier; Chris Tsoukas; Alain Piché
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-09       Impact factor: 2.471

6.  A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy.

Authors:  Lynn T Matthews; Janet Giddy; Musie Ghebremichael; Jane Hampton; Anthony J Guarino; Aba Ewusi; Emma Carver; Karen Axten; Meghan C Geary; Rajesh T Gandhi; David R Bangsberg
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

7.  Nucleoside-sparing antiretroviral regimens.

Authors:  Pola de la Torre; Jomy George; John D Baxter
Journal:  Curr Infect Dis Rep       Date:  2014-07       Impact factor: 3.663

8.  Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study.

Authors:  Johan J Van der Watt; Katalin A Wilkinson; Robert J Wilkinson; Jeannine M Heckmann
Journal:  BMC Infect Dis       Date:  2014-02-10       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.